Skip to Content
Merck
All Photos(1)

Key Documents

SML3203

Sigma-Aldrich

Tebipenem

≥98% (HPLC)

Synonym(s):

(1R,5S,6S)-2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-6-[(R)-1-hydroxyeth yl]-1-methyl-carbapen-2-em-3-carboxylic acid, (4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, L-084 active drug, LJC 11,036, LJC 11036, ME1211 active drug, SPR 859, SPR 994 active drug, SPR-859, SPR-994 active drug, SPR859, SPR994 active drug, TBM, TBM-PI active drug, Tebi-pivoxil active drug, [4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H21N3O4S2
CAS Number:
161715-21-5
Molecular Weight:
383.49
MDL number:
MFCD00936545
UNSPSC Code:
51111800
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1

InChI key

GXXLUDOKHXEFBQ-YJFSRANCSA-N

Biochem/physiol Actions

Tebipenem (LJC 11,036; SPR859; TBM) is a carbapenem class broad-spectrum β-lactam antibiotic against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strains (respective MIC ≤6-200 and ≤25-390 ng/mL), while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa (respective MIC ranges 0.2 to12.5, 0.05 to100, 3.13 to >100 μg/mL). TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Aileen Rubio et al.
ACS infectious diseases, 4(10), 1436-1438 (2018-08-18)
Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum
Qi Yao et al.
Molecules (Basel, Switzerland), 21(1), 62-62 (2016-01-12)
To systemically investigate the in vitro and in vivo antibacterial properties of tebipenem pivoxil tablet. In addition, acute toxicity of this preparation was also studied. In vitro, minimum inhibitory concentration (MIC) or minimal inhibitory concentration (MBC) were determined by using
M Hikida et al.
Antimicrobial agents and chemotherapy, 43(8), 2010-2016 (1999-08-03)
LJC 11,036 is the active metabolite of L-084, a novel oral carbapenem that exhibits potent broad-spectrum activity. Antibacterial activities of LJC 11,036 against clinical isolates from respiratory infections, such as Streptococcus pneumoniae (n = 52), Streptococcus pyogenes (n = 19)
Visanu Thamlikitkul et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97(12), 1259-1268 (2015-03-15)
To determine in vitro and in vivo activity of tebipenem against ESBL-producing E. coli. Minimum inhibitory concentration (MIC) of tebipenem against 100 clinical isolates of ESBL-producing E. coli was performed by broth micro-dilution technique. Blood and urine samples from 10
S Miyazaki et al.
Antimicrobial agents and chemotherapy, 45(1), 203-207 (2000-12-20)
L-084 (a prodrug of LJC 11,036 [L-036]) is a new oral carbapenem. Here we compared the in vitro and in vivo antibacterial activities of L-036 with those of imipenem, faropenem, ceditoren-pivoxil, cefdinir, amoxicillin, and levofloxacin. The MICs at which 90%
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service